India
· Delayed Price · Currency is INR Aurobindo Pharma Statistics
Total Valuation
Aurobindo Pharma has a market cap or net worth of INR 851.43 billion. The enterprise value is 854.72 billion.
| Market Cap | 851.43B |
| Enterprise Value | 854.72B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aurobindo Pharma has 580.80 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Shares Outstanding | 580.80M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 15.41% |
| Owned by Institutions (%) | 33.44% |
| Float | 275.89M |
Valuation Ratios
The trailing PE ratio is 24.39 and the forward PE ratio is 20.63. Aurobindo Pharma's PEG ratio is 1.23.
| PE Ratio | 24.39 |
| Forward PE | 20.63 |
| PS Ratio | 2.89 |
| PB Ratio | 2.88 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.23 |
Enterprise Valuation
| EV / Earnings | 24.27 |
| EV / Sales | 2.88 |
| EV / EBITDA | 13.64 |
| EV / EBIT | 17.93 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 1.06 |
| Debt / FCF | n/a |
| Interest Coverage | 14.82 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 8.71% |
| Revenue Per Employee | 11.42M |
| Profits Per Employee | 1.35M |
| Employee Count | 26,015 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.89% in the last 52 weeks. The beta is 0.53, so Aurobindo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +60.89% |
| 50-Day Moving Average | 1,507.85 |
| 200-Day Moving Average | 1,238.72 |
| Relative Strength Index (RSI) | 43.73 |
| Average Volume (20 Days) | 1,361,089 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aurobindo Pharma had revenue of INR 297.18 billion and earned 35.21 billion in profits. Earnings per share was 60.10.
| Revenue | 297.18B |
| Gross Profit | 168.15B |
| Operating Income | 47.82B |
| Pretax Income | 48.92B |
| Net Income | 35.21B |
| EBITDA | 62.17B |
| EBIT | 47.82B |
| Earnings Per Share (EPS) | 60.10 |
Balance Sheet
The company has 63.26 billion in cash and 66.48 billion in debt, giving a net cash position of -3.21 billion or -5.53 per share.
| Cash & Cash Equivalents | 63.26B |
| Total Debt | 66.48B |
| Net Cash | -3.21B |
| Net Cash Per Share | -5.53 |
| Equity (Book Value) | 298.51B |
| Book Value Per Share | 509.32 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 56.58%, with operating and profit margins of 16.09% and 11.85%.
| Gross Margin | 56.58% |
| Operating Margin | 16.09% |
| Pretax Margin | 16.46% |
| Profit Margin | 11.85% |
| EBITDA Margin | 20.92% |
| EBIT Margin | 16.09% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.00, which amounts to a dividend yield of 0.20%.
| Dividend Per Share | 3.00 |
| Dividend Yield | 0.20% |
| Dividend Growth (YoY) | -40.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | 0.20% |
| Earnings Yield | 4.10% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 20, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Jul 20, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |